Literature DB >> 4444228

[Pharmacocinetics and dosage of dextran 40 in relation to renal function (author's transl)].

H Köhler, W Kirch, D Höffler, P Koeppe.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4444228     DOI: 10.1007/BF01468621

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


× No keyword cloud information.
  14 in total

1.  METABOLISM IN VIVO OF CLINICAL DEXTRAN.

Authors:  E L ROSENFELD; A S SAIENKO
Journal:  Clin Chim Acta       Date:  1964-09       Impact factor: 3.786

2.  FURTHER STUDIES ON THE EFFECT OF DEXTRAN OF VARIOUS MOLECULAR WEIGHT ON THE COAGULATION MECHANISM.

Authors:  I M NILSSON; O EIKEN
Journal:  Thromb Diath Haemorrh       Date:  1964-04-15

3.  [The occurrence of dextranase in human tissue].

Authors:  R AMMON
Journal:  Enzymologia       Date:  1963-02-15

4.  Gastro-intestinal excretion of dextran-C14.

Authors:  B ABERG; W L BLOOM; E HANSSON
Journal:  Acta Physiol Scand       Date:  1961-06

5.  THE RENAL CLEARANCE OF DEXTRAN OF DIFFERENT MOLECULAR SIZES IN NORMAL HUMANS.

Authors:  G ARTURSON; G WALLENIUS
Journal:  Scand J Clin Lab Invest       Date:  1964       Impact factor: 1.713

6.  The splitting of dextran and isomaltose by animal tissues.

Authors:  E L ROSENFELD; I S LUKOMSKAYA
Journal:  Clin Chim Acta       Date:  1957-04       Impact factor: 3.786

7.  Bleeding time prolongation after dextran infusion.

Authors:  E ADELSON
Journal:  Bibl Haematol       Date:  1958

8.  Metabolism of plasma expanders studied with carbon-14-labeled dextran.

Authors:  I GRAY
Journal:  Am J Physiol       Date:  1953-09

9.  [Quantitative micro determination of dextran. I. In body fluids].

Authors:  W Appel; V Wirmer; D Sprengard
Journal:  Z Klin Chem Klin Biochem       Date:  1968-09

10.  [Studies on the fate of injected dextran in the guinea pig].

Authors:  K H Ebert; G Schenk; R Scholz
Journal:  Z Klin Chem Klin Biochem       Date:  1968-09
View more
  5 in total

1.  [The elimination of hydroxyethyl starch 200/0.5, dextran 40 and oxypolygelatine (author's transl)].

Authors:  H Köhler; H Zschiedrich; A Linfante; F Appel; H Pitz; R Clasen
Journal:  Klin Wochenschr       Date:  1982-03

2.  Elimination of hexamethylene diisocyanate cross-linked polypeptides in patients with normal or impaired renal function.

Authors:  H Köhler; W Kirch; P Fuchs; K Stalder; A Distler
Journal:  Eur J Clin Pharmacol       Date:  1978-12-18       Impact factor: 2.953

3.  [Prophylaxis and therapy of shunt thrombosis in terminal renal insufficiency (author's transl)].

Authors:  H Köhler
Journal:  Klin Wochenschr       Date:  1977-01-15

4.  Bunazosin in patients with impaired hepatic or renal function.

Authors:  A Halabi; A Nokhodian; W Kirch
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1993 Jul-Sep       Impact factor: 2.441

Review 5.  Clinical pharmacokinetic considerations in the use of plasma expanders.

Authors:  U Klotz; H Kroemer
Journal:  Clin Pharmacokinet       Date:  1987-02       Impact factor: 6.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.